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Abstract
Background: Brain tumors represent an important cause of cancer-related death in adolescents and young adults. Most are
diagnosed in low-income and middle-income countries. We aimed to conduct the first, to our knowledge, systematic review
of time trends and geographical variation in survival in this age group. Methods: We included observational studies
describing population-based survival from astrocytic tumors in patients aged 15-39 years. We queried 6 electronic databases
from database inception to December 31, 2019. This review is registered with PROSPERO, number CRD42018111981. Results:
Among 5640 retrieved records, 20 studies fulfilled the inclusion criteria. All but 1 study focused on high-income countries.
Five-year survival from astrocytoma (broad morphology group) mostly varied between 48.0% and 71.0% (1973-2004) without
clear trends or geographic differences. Adolescents with astrocytoma had better outcomes than young adults, but survival
values were similar when nonmalignant tumors were excluded. During 2002-2007, 5-year survival for World Health
Organization grade I-II tumors was in the range of 72.6%-89.1% in England, Germany, and the United States but lower in
Southeastern Europe (59.0%). Five-year survival for anaplastic astrocytoma varied between 39.6% and 55.4% (2002-2007). Five-
year survival from glioblastoma was in the range of 14.2%-23.1% (1991-2009). Conclusions: Survival from astrocytic tumors
remained somewhat steady over time, with little change between 1973 and 2009. Survival disparities were difficult to
examine, because nearly all the studies were conducted in affluent countries. Studies often adopted the International
Classification of Childhood Cancer, which, however, did not allow to accurately describe variation in survival. Larger studies
are warranted, including underrepresented populations and providing more recent survival estimates.
Primary tumors of the central nervous system (CNS) are rare. In
adolescents and young adults (15-39 years), the estimated
world-standardized incidence rate was 15 new cases per million
in 2018, ranging from 29 in Western Europe to 4.4 in Eastern
Africa (1). Although uncommon, in 20- to 39-year-olds, CNS
tumors ranked second among the leading causes of cancer-
related deaths in countries with very high human development
index (2). Adolescents and young adults (15-39 years) are
patients with distinct needs, and services provided for children
and older adults may not be adequate (3).
In adolescents and young adults, almost 80% of CNS tumors
are diagnosed in low-income and middle-income countries (1).
Where the burden of CNS tumors is highest, however, patients
may encounter obstacles in being diagnosed and treated for
their disease. For instance, access to radiotherapy is extremely
unequal worldwide. Density of radiotherapy machines varies
between 4.9 or more per million population in Western Europe,
North America, Australia, and Japan and 0.4 per million in the
rest of the world (4). The divide between the number of diagno-
ses and the availability of treatment facilities will inevitably
translate to missed opportunities of care (and cure), years of life
lost, and financial hardship in families where patients are the
breadwinners.
Mortality is a key indicator in epidemiological surveillance,
but it does not provide information on the course of the disease
following a cancer diagnosis. By contrast, population-based sur-
vival incorporates the follow-up component and reflects the
overall effectiveness of a health-care system in managing that
cancer (5,6).
The CNS comprises brain, spinal cord, and meninges. Brain
tumors are, by far, the most important group. In the third cycle
of the CONCORD programme, broad disparities in survival
emerged among more than 650 000 adults who were diagnosed
with a primary brain tumor in 58 countries worldwide during
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2000-2014. Age-standardized 5-year net survival for all brain tu-
mor subtypes and all ages combined (15-99 years) ranged be-
tween 14.7% in Thailand and 42.2% in Croatia.
Brain tumor morphology is the most important predictor of
clinical outcome. In patients aged 15-44 years, the European av-
erage 5-year relative survival during 2000-2007 was 14.2% for
glioblastoma but 56.1% for lower grade astrocytic tumors (7).
For adolescents and young adults diagnosed with a given
brain tumor subtype, it is currently not known how survival
varies around the world and whether it has improved over time.
As age increases from childhood to early adulthood, the
morphology distribution shifts progressively from a predomi-
nance of low grade gliomas (eg, pilocytic astrocytoma) to a
higher proportion of more aggressive tumors. The use of the
International Classification of Childhood Cancer (ICCC) has
been often extended to adolescents and young adults (8,9), but
in light of the differences in the morphology distribution, it is
unclear whether alternative strategies should be adopted.
We aimed to address these questions by systematically syn-
thesizing the scientific evidence pertaining to population-based
survival from brain tumors in adolescents and young adults.
Methods
This systematic review focused on prospective, observational
studies presenting survival from brain tumors in adolescents
and young adults.
We queried 6 electronic databases (Dissertation and Theses
Global, Embase, MEDLINE, Open Grey, Scopus, and Web of
Science) from database inception to December 31, 2019. Search
strategies were specific to each database and included terms re-
ferring to 4 domains: disease, statistical method, study design,
and outcome. A professional librarian at the London School of
Hygiene and Tropical Medicine reviewed the search strategies
(Supplementary Table 1, available online).
There is no consensus on the definition of “young adults,”
and in most studies the upper age boundary varied between 24
and 39 years. We adopted a comprehensive approach by includ-
ing patients aged 15-39 years. However, studies including indi-
viduals who overlapped this age range were still eligible.
We extracted data from published reports. Eligible studies
had to include survival estimates from primary data collected in
population-based cancer registries. For a given country or re-
gion, hospital-based estimates were retained only if no
population-based estimates were available.
Studies were eligible if they included estimates derived from
a time-to-event analysis and survival probabilities up to at least
5 years. More specifically, survival probabilities had to be esti-
mated as observed survival, relative survival, or net survival
(10). These outcome measures do not require knowledge of the
cause of death.
We did not put restrictions relating to language and we con-
sidered both published articles and grey literature, such as con-
ference abstracts and statistical reports. However, because
morphology classifications changed substantially after 1995, we
did not include earlier reports. If a study did not clearly meet
the eligibility criteria, we decided on inclusion or exclusion
through discussion.
We were interested in both nonmalignant and malignant
brain tumors. We focused on astrocytic tumors because data for
rarer subtypes were too scanty to allow robust comparisons.
Because morphological groupings differed between studies,
we combined similar definitions (eg, anaplastic astrocytoma
and astrocytoma World Health Organization [WHO] grade III)
under a common descriptor (Supplementary Table 2, available
online) but, where possible, without combining morphologies
with different clinical behavior (ie, WHO grade). Definitions
sharing the same code in the International Classification of
Diseases for Oncology (ICD-O) Third Edition were merged (11).
Then we conducted a sensitivity analysis by regrouping mor-
phologies according to the Surveillance Epidemiology and End
Results Adolescents and Young Adults (SEER AYA) Site Recode
to explore whether less granular categories were equally infor-
mative (12). SEER AYA Site Recode is based on the classification
proposed by Birch and Barr for tumors diagnosed in adolescents
and young adults (13,14). SEER AYA Site Recode subdivides as-
trocytic tumors into 3 categories: low grade tumors, glioblas-
toma plus anaplastic astrocytoma, and astrocytoma not
otherwise specified (NOS) (12).
From each eligible study, we abstracted 5-year survival prob-
abilities by morphology. When studies provided survival esti-
mates for more than 1 calendar period or considered more than
1 age group (eg, patients aged 15-19 years and 20-24 years), each
estimate was considered separately. Where available, we col-
lected specifications on the reference classification used for
morphology definitions, data quality indicators (eg, proportion
of microscopically verified tumors, patients lost to follow-up,
and poorly specified/unspecified morphologies), and complete-
ness of ascertainment.
Calendar periods differed between studies, and their length
also varied. Therefore, we have presented the results labeled
with the middle year of the calendar period.
The systematic review is registered with PROSPERO, number
CRD42018111981.
Results
The database search yielded 5640 records. We screened these
records for eligibility from the title and the abstract. We then
assessed the full text of the remaining 356 publications for eligi-
bility. This process followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses guidelines (Figure 1)
(15). Twenty studies were included in the systematic review.
The calendar period for incident cases ranged from 1968 to
2014. Twelve studies (60%) were conducted in 1 or more
European countries, 4 in the United States, 2 in Asia (South
Korea and Japan), 1 comprised patients from the United States
and Germany, and 1 international study was carried out in
Europe but also included Cyprus and Turkey and the United
States. Only 1 study included any data from middle-income
countries (Table 1) (33).
Young adults were defined as individuals up to the age of
24 years in 6 studies, up to age 39 in 7 studies, and up to age 44
in 3 studies. Two studies adopted alternative age definitions of
the upper boundary (29 or 40 years). The eligible studies collec-
tively provided 75 survival estimates: 14 for adolescents only
(15-19 years), 23 for young adults (20 years or more) only, and 38
estimates for adolescents and young adults combined (Table 1).
Eight of the 20 studies had regional population coverage, 4
were based on national registries, 7 were international studies
drawing data from both regional and national registries, and in
1 study the information was not available (Table 1).
The completeness of ascertainment was specified in only 4
of the 20 studies (17,20,22,28). Twelve (60%) of the 20 studies
provided details on data quality indicators: 2 studies specified
only the criteria for exclusions (eg, diagnoses based on death
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certificate only or autopsy), and 10 reported at least the propor-
tion of microscopically verified tumors (Table 1).
The proportion of microscopically verified tumors referred
specifically to brain tumors in 4 studies (7,30,33,34), and in 5 the
parameter was for all tumors combined (16,20,21,32,35). In the 2
international comparisons, the proportion of microscopically
verified tumors varied between 57.2% and 96.4% (South-Eastern
European [SEE] Consortium, plus the United States), and be-
tween 61.0% and 100% in the European Cancer Registry based
study on survival and care of cancer patients (EUROCARE) 5
study, covering adolescents and young adults diagnosed during
1999-2007 in 27 European countries (7,33). One study comprised
exclusively patients with microscopically verified tumors
(Supplementary Table 3, available online) (24).
Five studies did not clarify the reference classification. In the
remaining 15 studies, the second or third editions of ICD-O were
the reference classification (Table 1) (11,36).
Ten of the 20 eligible studies grouped all astrocytic morpholo-
gies under the broad definition “astrocytoma,” but 2 of these
studies did not clarify the behavior of eligible tumors (only malig-
nant, or both malignant and nonmalignant) (Supplementary
Table 3, available online) (23,27). Ten studies considered either
subgroups (ie, low grade astrocytoma or high grade astrocytoma)
or single morphologies (eg, diffuse astrocytoma, glioblastoma).
5640 potentially eligible records 
339 records identified through Dissertation and Theses Global 
1469 records identified through Embase 
796  records identified through Medline 
19  records identified through Open Grey 
2748 records identified through Scopus 
263 records identified through Web of Science 
6 records identified through additional sources 
4486 records screened for eligibility at abstract and title level 
1154 duplicates excluded 
356 records assessed for eligibility at full-text level 
4130 records excluded 
336 records excluded 
 4 presenting, for a given country or region, 
hospital-based estimates in presence of 
population-based estimates 
44 considering countries/regions or populations 
included in more recent augmented studies (eg 
larger sample size longer follow-up, larger 
geographical coverage)
23 published before 1995
60 ineligible design or noninformative reports
59 ineligible outcome measure 
  8 ineligible topography 
69 ineligible morphology 
54 ineligible age group 
15 presenting estimates for children and adults 
combined 
20 studies included in the systematic review 
Figure 1. Preferred reporting items for Systematic Reviews and Meta-Analyses flowchart.
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In 13 studies (65%), the outcome measure was observed sur-
vival (ie, all-cause survival), and in 7 studies it was relative sur-
vival (Table 1).
For astrocytoma as a broad morphology group, survival esti-
mates referred mostly to patients aged 15-24 years. No studies
were available from low-income or middle-income countries.
Nearly all estimates of 5-year survival fell within the range of
48.0%-71.0% during 1973-2004, with little variation in survival
between countries or over time (16–19,21–24,28,32). In the only
US study, however, 5-year survival was higher than in Europe:
73.1% vs 65.0% around 1988, and 81.3% vs 64.2% around 2000
(20). In the EUROCARE-5 study for diagnoses during 2000-2007,
5-year survival from astrocytoma was 50.8% in adolescents (15-
19 years), similar (47.6%) in patients up to 34 years old, but lower
(38.7%) in the 35- to 39-year age group (Figure 2) (32). One study
from Portugal, however, found that 5-year survival from astro-
cytoma was remarkably higher in young adults (20-24 years)
than in adolescents (81.3% vs 55.5%), but confidence intervals
were wide and largely overlapping because of the very small
study population (51 patients overall) (23).
Among the studies using the broad definition “astrocytoma,”
we identified 4 possible combinations of age (adolescents [15-
19 years] or adolescents and young adults combined [15-
44 years]) and tumor behavior (all behaviors or malignant only).
Five-year survival from nonmalignant and malignant astrocy-
toma combined was slightly higher in adolescents (15-19 years,
60.1%-81.3%) than in the broader age group (15-44 years, 48.0%-
68.4%) except in Eastern Europe and France, where values were
Trama et al., 2016 (32)
Trama et al., 2016 (32)
Trama et al., 2016 (32)
Trama et al., 2016 (32)
Trama et al., 2016 (32)
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Carreira et al., 2012 (23)
Gatta et al., 2009 (21)
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Figure 2. Five-year survival (percentage) from astrocytoma (broad morphology group). Error bars are 95% confidence intervals. For studies providing only point survival
estimates, confidence intervals are shown as (survival estimate 61%).
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lower (52.0%) (18,19). Conversely, 5-year survival for malignant
astrocytoma in adolescents was very similar to the values ob-
served in adolescents and young adults combined (Figure 3).
Five-year survival from low grade astrocytoma (WHO grade I
and II combined) was 87.0% or more for patients aged 16-
29 years in England, Germany, and the United States (2002-
2005). In the same countries, survival was lower (72.6%-76.0%)
when individuals up to age 39 years were also included
(26,27,33). In the SEE consortium, 5-year survival for patients di-
agnosed in 2005 was much lower (59.0%, 15- to 39-year-olds)
(Figure 4) (33).
Five-year survival from high grade astrocytoma (WHO grade
III and IV combined) was 18.0% in England in 1997 (27), whereas it
varied between 27.3% and 39.2% in Germany, the United States,
and the SEE consortium during 2002-2005 (Figure 4) (26,33).
Five-year survival from diffuse astrocytoma was in the
range of 62.9%-75.9% in Germany and the United States dur-
ing 2002-2007 (26,33,34). In the EUROCARE-5 consortium (27
European countries combined) and the SEE consortium
(Southern and Eastern Europe), the average 5-year survival
was 56.1% (2003) and 55.0% (2005), respectively (Figure 4)
(7,33).
The survival probability at 5 years for South Korean patients
diagnosed with anaplastic astrocytoma in 2002 was 39.6% (24).
In the United States, 5-year survival was higher: 50.4% in 2003
and 55.4% in 2007 (Figure 4) (29,34).
Five-year survival from glioblastoma was in the range of
14.2%-23.1% in England, the EUROCARE-5 consortium, the
United States, and South Korea without improvements in the
20 years between 1991 and 2009 (Figure 4) (7,24,25,30,34).
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Figure 3. Five-year survival (percentage) from astrocytoma (broad morphology group) by age group (adolescents, or adolescents and young adults combined) and tumor
behavior (nonmalignant plus malignant, or malignant only). Error bars are 95% confidence intervals. For studies providing only point survival estimates, confidence
intervals are shown as (survival estimate61%).
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Last, studies were grouped according to SEER AYA Site
Recode (12). Such system does not adopt the broad definition
“astrocytoma,” so studies using this definition were excluded
from the analysis. None of the studies focused solely on adoles-
cents (15-19 years). Five-year survival from low grade astrocytic
tumors was in the range of 71.4%-93.4% (26,27,31,33,34). Five-
year survival from high grade astrocytic tumors varied between
14.2% and 55.4% (7,24–27,29,30,33,34). Five-year survival for as-
trocytoma NOS was in the range of 55.0%-75.9% (Supplementary
Figure 1, available online) (7,26,33).
Discussion
To our knowledge, this is the first systematic review summariz-
ing international trends in survival from astrocytic tumors in
adolescents and young adults (15-39 years).
Outcomes remained somewhat steady over time, with little
change over the 35 years between 1973 and 2009. Five-year sur-
vival for all astrocytic tumors combined was mostly in the range
of 48.0%-71.0%. Survival was much lower in studies including
only patients with malignant astrocytoma or considering
broader age groups.
Five-year survival was in the range of 55.0%-75.9% for diffuse
astrocytoma, but it rose up to 89.1% when WHO grade I and II
tumors were combined. The survival probability at 5 years was
23.1% or less for glioblastoma, in the range of 39.6%-55.4% for
anaplastic astrocytoma, and mostly between 27.3% and 39.2%
when the 2 morphologies were jointly considered. For a given
morphology, older patients experienced poorer outcomes.
Nearly all the studies were conducted in high-income coun-
tries, noticeably in high-income countries in Europe, and in the
United States. In these settings, survival was similar. Only 1
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Figure 4. Five-year survival (percentage) from astrocytoma (low grade), pilocytic astrocytoma, diffuse astrocytoma, astrocytoma (high grade), anaplastic astrocytoma,
and glioblastoma. Error bars are 95% confidence intervals. For studies providing only point survival estimates, confidence intervals are shown as (survival estimate
61%).
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international study included patients diagnosed in middle-
income countries (Belarus, Bulgaria, Montenegro, Romania,
Serbia, Turkey, Ukraine). In this study (SEE consortium), the av-
erage 5-year survival for low grade astrocytic tumors was at
least 15% lower than in more affluent countries (England,
Germany, and the United States), but the gap in survival was
smaller (approximately 10%) for high grade astrocytic tumors,
for which little can be done (33).
Eleven out of 20 studies (55%) extended the use of ICCC to
adolescents and young adults, using the broad definition
“astrocytoma.” We were obliged to retain such definition in our
analyses because these 11 studies did not stratify survival esti-
mates by tumor subtype (eg, diffuse astrocytoma, glioblastoma)
or WHO grade (ie, low grade and high grade), leading to a loss of
precision and hampering the interpretation of results. The dis-
tribution of astrocytic tumors with different clinical behavior
varies widely with age. Pilocytic astrocytoma, the most common
nonmalignant astrocytic tumor, accounts for 60% of all astro-
cytic tumors in children compared with 47% in adolescents (15-
19 years) and 19% in the 15- to 39-year-olds (34). Pilocytic astro-
cytoma is associated with a survival probability at 5 years of
around 90%, whereas survival for higher grade astrocytoma is
50% or less (34). Therefore, any grouping strategy combining
morphologies with very different outcomes will result in in-
flated, misleading survival estimates.
When we stratified the 11 studies using the information
they provided on the eligible tumor behaviors, survival trends
in adolescents (15-19 years) became slightly clearer, with lower
5-year survival when nonmalignant astrocytic tumors were ex-
cluded. When broader age groups were considered (upper age
limit of 24 years or more), however, survival was similar after in-
clusion or exclusion of patients with nonmalignant astrocytic
tumors. These tumors are rare in older adults, and their impact
on survival estimates for the broad morphology “astrocytoma”
is likely to be smaller with increasing age. Yet, in Eastern
European adolescents, survival for all-behavior astrocytoma
was in line with the values observed for malignant-only astro-
cytoma (18,19). Such a finding suggests underregistration of
nonmalignant tumors.
We found that 5-year survival from astrocytoma in adoles-
cents and young adults mostly varied between 48.0% and 71.0%
during 1973-2004. Conversely, in children (0-14 years), survival
from astrocytoma varied between 71.0% and 89.0% in most
countries during 1970-2009 (37). Differences in survival between
the 2 age groups, however, were less remarkable when more
granular morphology definitions, instead of ICCC, were used,
but studies adopting such strategy were scarce (37). Such dis-
crepancy emphasizes the limitations of ICCC in accounting for
the substantial differences in the morphology distribution of as-
trocytic tumors between children, and adolescents and young
adults.
The classification proposed by Birch and Barr for tumors di-
agnosed in adolescents and young adults formed the basis of
SEER AYA Site Recode (12–14), which implemented a bespoke
classification scheme for adolescents and young adults in a
large, population-based cancer registry. This classification
scheme aimed to address the ICCC limitations by using WHO
grade to further subdivide astrocytic tumors. We tried to re-
group the studies based on SEER AYA Site Recode
(Supplementary Figure 1, available online). Only 1 study
adopted this classification, so we were obliged to mainly use
the original morphology definitions (27). Five-year survival from
low-grade astrocytic tumors was mostly in the range of 71.4%-
93.4% during 1997-2007, and 5-year survival from high grade
astrocytic tumors varied between 14.2% and 55.4% during 1991
and 2009. Survival for low-grade astrocytic tumors was remark-
ably higher than for anaplastic astrocytoma and glioblastoma,
suggesting that SEER AYA Site Recode may be more appropriate
than ICCC in describing survival in adolescents and young
adults. The variation in survival within each morphology group,
however, implies that combining different morphologies may
still result in some loss of information. This seems particularly
relevant to high grade morphologies, namely, anaplastic astro-
cytoma and glioblastoma. Anaplastic astrocytoma often recurs
as glioblastoma, but outcomes at 5 years are remarkably differ-
ent (Supplementary Figure 1, available online) (34). Further re-
search is needed to understand whether SEER AYA Site Recode
may replace ICCC in studies exploring survival disparities be-
tween children, and adolescents and young adults (12).
SEER AYA Site Recode also comprises the category astrocy-
toma NOS. In most of the studies using such definition, survival
estimates were in the range of 55.0%-75.9% (7,26,33). These val-
ues are in line with those observed for diffuse astrocytoma
(WHO grade II) (34). In ICD-O-3, diffuse astrocytoma is one of the
alternative descriptors of astrocytoma NOS (11). Conversely, in
the WHO classification (4th edition), astrocytoma NOS is not a
separate definition and the corresponding ICD-O-3 code is at-
tributed to diffuse astrocytoma (38). Given that the definitions
“astrocytoma not otherwise specified” and “diffuse
astrocytoma” refer to the same entity, we recommend against
using the definition “astrocytoma NOS” as a synonym for
unspecified astrocytic tumors (Supplementary Figure, available
online).
Overall, there were no clear trends in 5-year survival from
astrocytoma as a broad morphology group. In the United States,
however, survival for adolescents (15-19 years of age) rose from
60.1% to 81.3% during the 2 decades between 1977 and 1997 (20).
Conversely, survival for adolescents in Europe persisted in the
range of 64.2%-66.0% during 1988-2001 (16,18,21). These findings
may suggest that in the United States, outcomes for adolescents
improved earlier than elsewhere, possibly due to the implemen-
tation of dedicated health services.
In adolescents and young adults, more than one-fourth of
astrocytic tumors are glioblastomas (34). In 2005, a randomized
clinical trial showed that 2-year survival was 26.5% in patients
treated with radiotherapy plus temozolomide chemotherapy
and only 10.4% in those receiving radiotherapy (39). The con-
comitant treatment has since become the standard of care for
adults younger than 70 years. We could not explore the benefit
of this treatment protocol at the population level, because very
few survival estimates are available for patients diagnosed after
2005. In this systematic review, 5-year survival was in the range
of 14.2%-23.1%. In older adults (40 years or older), 5-year survival
is below 10%. Glioblastoma is defined as primary when it arises
as a WHO grade IV lesion and secondary if it has developed
from a lower grade glioma. Secondary glioblastomas are charac-
terized by mutation of the isocitrate dehydrogenase (IDH) gene.
Patients with IDH-mutated glioblastomas are younger than
those affected by IDH wild-type glioblastomas (median age at
diagnosis 32 years vs 59 years) and have a more favorable out-
come (40). We chose to report only 5-year survival to improve
comparability between studies, because it was the most com-
monly adopted outcome measure. For glioblastoma, however,
shorter term survival estimates may be more informative.
Information on data quality indicators was inadequately
reported and often totally missing (42% of studies). Data quality
indicators tell us about cancer registry practices (eg, sources of
data, type of follow-up) and affect the reliability of the data (41).
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Most frequently, studies indicated the proportion of microscopi-
cally verified tumors. Histologic confirmation of brain tumors
may not be possible if the patient is clinically unfit for surgery
or a biopsy, or if tumor location bars a diagnostic procedure. In
each of the 2 large international studies reviewed here, the pro-
portion of microscopically verified tumors varied widely be-
tween the participating registries. The average proportion of
microscopically verified tumors in these 2 studies was similar
(around 80%), but the SEE consortium also included middle-
income countries, where access to care may be suboptimal
(7,33). In some of the more affluent European countries, how-
ever, the proportion of microscopic verification was also rather
low (eg, 63.3% in Italy) (7). Proportions that are very high may in-
dicate overreliance on pathology reports and, therefore, a re-
stricted number of data sources, leading to incompleteness of
case ascertainment. Furthermore, patients with microscopically
verified brain tumors may not necessarily represent the whole
population, because they were at least able to undergo an inva-
sive diagnostic procedure. If only these patients are included in
the study, survival estimates may be higher. The overall com-
pleteness of case ascertainment was specified only in 4 studies,
where it was 95% or more. Lower levels may suggest that a can-
cer registry fails to capture all the data within its catchment
area, and this may lead to underascertainment of brain tumors
(42).
Two-thirds of the studies estimated survival as all-cause
survival (ie, observed survival). The cause of death is not used
in international comparisons of cancer survival, because it may
be unavailable or based on unreliable information from the
death certificate (43–45). Observed survival can be readily
obtained, but it is biased downward because it includes death
from other causes (ie, background mortality). Background mor-
tality varies between populations and over time, and it can be
derived from life tables (46). Once competing risks of death are
properly accounted for, the estimate will reflect net survival,
which is the survival attributable exclusively to cancer. Net sur-
vival permits robust international comparisons, and it can now
be directly estimated with the nonparametric, unbiased Pohar
Perme estimator (10). Until recently, relative survival has been
used as the best approximation of net survival, but this indica-
tor does not allow for informative censoring. Informative cen-
soring arises when the probability of dying from cancer is not
independent of the probability of dying from other causes, and
this is more frequent in the elderly. We have been obliged to
compare studies that used different survival estimators, which
may reduce the validity of some comparisons. Nevertheless,
given that we considered relatively young patients and nearly
all were diagnosed in affluent countries, failing to account for
the rather low background mortality is unlikely to lead to sub-
stantial bias.
This systematic review presents some limitations. We
adopted a wide range of morphology definitions to summarize
survival variation in as much detail as possible. However, the
number of survival estimates in some categories was small,
hindering robust comparisons.
Many studies (75%) were partly or entirely based on regional
data. We assumed that regional survival estimates applied to
the whole country, but this assumption may not hold if provi-
sion of cancer care is unequally distributed. However, these
regions were often also included in national or international
studies. Estimates from studies with different geographical cov-
erage did not differ substantially, so findings from smaller stud-
ies were fairly generalizable.
We were obliged to present trends using the central year of
the calendar period covered by a given study regardless of its
length. Although this strategy improved clarity, when 2 or more
calendar periods overlapped, we could not use differences in
length to explore nonlinear changes in survival. However, there
were no substantial gains in survival for any of the morpholo-
gies, so comparisons referring to the central year may be
acceptable.
In conclusion, there is a striking gap in knowledge about sur-
vival trends in middle-income and low-income countries,
where disparities in access to care are reported (4). Studies with
a wider scope extending to currently underrepresented geo-
graphical regions could fill this gap. Moreover, standardized
data collection, data quality control, and data analysis using the
same statistical methods are required to reduce heterogeneity
and enable robust international comparisons. ICCC does not al-
low accurate reporting of survival from astrocytic tumors in
adolescents and young adults because it does not account for
the substantial differences in the histology distribution of brain
tumors between adolescents and young adults, and children.
Ultimately, ICCC should be revised. SEER AYA Site Recode,
which proposes granular morphology groupings based on WHO
grade, may inform such revision. Future studies should use im-
proved classification systems to properly explore potential out-
come disparities in adolescents and young adults and to inform
cancer control plans.
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